Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies : Episode 6
Treatment with Teclistamab Following Progression on CAR-T in R/R MM
The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.
EP: 1.Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
EP: 2.Selecting Patients with MM for Teclistamab and Optimal Sequencing
EP: 3.Mechanism of Action of Teclistamab in R/R MM and Data Updates
EP: 4.Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
EP: 5.Bispecific Antibodies in Development for the Treatment of R/R MM
Now Viewing
EP: 6.Treatment with Teclistamab Following Progression on CAR-T in R/R MM
EP: 7.Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
EP: 8.Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
EP: 9.The Development of Bispecifics-Based Combination Therapies in MM
EP: 10.Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
EP: 11.Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM
EP: 12.Recent Data on Non-BCMA Targeting Bispecifics in R/R MM
EP: 13.Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
